Literature DB >> 6221694

Serum bactericidal activity of ceftazidime and cefoperazone alone or in combination with amikacin against Pseudomonas aeruginosa and Klebsiella pneumoniae.

Y Van Laethem, H Lagast, J Klastersky.   

Abstract

Sera of volunteers receiving ceftazidime (2 g) or amikacin (500 mg), alone or in combination, or cefoperazone (2, 4, or 6 g) or cefoperazone (2 g) with amikacin (500 mg) were evaluated for bactericidal activity against Klebsiella pneumoniae and Pseudomonas aeruginosa. Serum bactericidal activities were similar for ceftazidime and ceftazidime plus amikacin, but were definitely lower for amikacin alone. Against P. aeruginosa, a 6-g dose of cefoperazone resulted in a higher frequency of peak serum bactericidal activities greater than or equal to 1:8 than a 2-g dose of cefoperazone plus amikacin. Killing studies, performed in 1:8 diluted serum, demonstrated a higher killing rate for cefoperazone plus amikacin than for a 6-g dose of cefoperazone, the more resistant P. aeruginosa excepted. Emergence of resistance was found with a 2-g dose of cefoperazone for K. pneumoniae and with a 6-g dose of cefoperazone for P. aeruginosa, but not with cefoperazone plus amikacin.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6221694      PMCID: PMC184666          DOI: 10.1128/AAC.23.3.435

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  14 in total

1.  Antibacterial activity in serum and urine as a therapeutic guide in bacterial infections.

Authors:  J Klastersky; D Daneau; G Swings; D Weerts
Journal:  J Infect Dis       Date:  1974-02       Impact factor: 5.226

2.  Simplified, accurate method for antibiotic assay of clinical specimens.

Authors:  J V Bennett; J L Brodie; E J Benner; W M Kirby
Journal:  Appl Microbiol       Date:  1966-03

3.  Cephradine concentrations in serum, pleural fluid, pleura, and lung of normal rabbits.

Authors:  S A Sahn; J T Good; L B Reller
Journal:  J Antimicrob Chemother       Date:  1981-10       Impact factor: 5.790

Review 4.  Synergistic combinations of antibiotics in gram-negative bacillary infections.

Authors:  J Klastersky; S H Zinner
Journal:  Rev Infect Dis       Date:  1982 Mar-Apr

5.  Clinical evaluation of cefotaxime for therapy of lower respiratory tract infections.

Authors:  C J Schleupner; J C Engle
Journal:  Antimicrob Agents Chemother       Date:  1982-02       Impact factor: 5.191

6.  Cefoperazone (T-1551), a new semisynthetic cephalosporin: comparison with cephalothin and gentamicin.

Authors:  R N Jones; P C Fuchs; A L Barry; T L Gavan; H M Sommers; E H Gerlach
Journal:  Antimicrob Agents Chemother       Date:  1980-04       Impact factor: 5.191

7.  GR-20263: a new aminothiazolyl cephalosporin with high activity against Pseudomonas and Enterobacteriaceae.

Authors:  L Verbist; J Verhaegen
Journal:  Antimicrob Agents Chemother       Date:  1980-05       Impact factor: 5.191

8.  Moxalactam therapy of infections caused by cephalothin-resistant bacteria: influence of serum inhibitory activity on clinical response and acquisition of antibiotic resistance during therapy.

Authors:  R Platt; S L Ehrlich; J Afarian; T F O'Brien; J E Pennington; E H Kass
Journal:  Antimicrob Agents Chemother       Date:  1981-09       Impact factor: 5.191

9.  Clinical evaluation of moxalactam.

Authors:  W K Livingston; A M Elliott; W E Dismukes; C K Avent; C G Cobbs
Journal:  Antimicrob Agents Chemother       Date:  1981-07       Impact factor: 5.191

10.  Moxalactam therapy for bacterial infections.

Authors:  D J Winston; R W Busuttil; T O Kurtz; L S Young
Journal:  Arch Intern Med       Date:  1981-11
View more
  21 in total

Review 1.  Empiric treatment of infection during granulocytopenia: a comprehensive approach.

Authors:  J Klastersky
Journal:  Infection       Date:  1989 Mar-Apr       Impact factor: 3.553

2.  Serum bactericidal activity and killing rate for volunteers receiving imipenem, imipenem plus amikacin, and ceftazidime plus amikacin against Pseudomonas aeruginosa.

Authors:  P Van der Auwera; J Klastersky; H Lagast; M Husson
Journal:  Antimicrob Agents Chemother       Date:  1986-07       Impact factor: 5.191

3.  Serum bactericidal activity of mezlocillin, ceftazidime, mezlocillin/ceftazidime and mezlocillin/amikacin against Klebsiella pneumoniae and Pseudomonas aeruginosa.

Authors:  Y Van Laethem; J Klastersky
Journal:  Eur J Clin Microbiol       Date:  1986-02       Impact factor: 3.267

4.  Comparison of the serum bactericidal activity of ceftriaxone/piperacillin and ceftriaxone/netilmicin.

Authors:  K Machka; M Röbl; I Braveny
Journal:  Eur J Clin Microbiol       Date:  1986-02       Impact factor: 3.267

Review 5.  Serum bactericidal test.

Authors:  C W Stratton
Journal:  Clin Microbiol Rev       Date:  1988-01       Impact factor: 26.132

6.  Serum bactericidal activity of two newer quinolones against Salmonella typhi compared with standard therapeutic regimens.

Authors:  M Trautmann; B Krause; D Birnbaum; J Wagner; V Lenk
Journal:  Eur J Clin Microbiol       Date:  1986-06       Impact factor: 3.267

7.  Measurement of bactericidal activity in body fluids as a clinical research procedure.

Authors:  P Dejace; J Klastersky
Journal:  Eur J Clin Microbiol       Date:  1986-02       Impact factor: 3.267

Review 8.  Standardization of the serum bactericidal test and its relationship to levels of antimicrobial agents.

Authors:  C W Stratton
Journal:  Eur J Clin Microbiol       Date:  1986-02       Impact factor: 3.267

9.  Bactericidal activity of ceftazidime in serum compared with that of ticarcillin combined with amikacin.

Authors:  H C Standiford; G L Drusano; B Fitzpatrick; B Tatem; S C Schimpff
Journal:  Antimicrob Agents Chemother       Date:  1984-09       Impact factor: 5.191

10.  Three-step empiric treatment for severely neutropenic patients with fever: ceftazidime--vancomycin--amphotericin B.

Authors:  H Koeppler; K H Pflueger; R Seitz; K Havemann
Journal:  Infection       Date:  1989 May-Jun       Impact factor: 3.553

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.